AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00897260 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Description: DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
Study NCT00897260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Study NCT01101087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolock
Study NCT01101087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
Study NCT04084665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab
Study NCT03068052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No incentive
Description: Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment.
Study NCT03068052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment, for which they will received a loss-framed incentive. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment and will receive an additional unconditional pro-social incentive.
Study NCT02114398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual treatment
Description: usual treatment
Study NCT02114398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual treatment + sophrology
Description: usual treatment + sophrology
Study NCT03521401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
Study NCT06532929 — intervention group
Intervention type: DEVICE
Intervention: Orthopaedic surgeries
Description: rotator cuff repair or closure of capsule after arthroplasty surgery
Study NCT06532929 — intervention group
Intervention type: DEVICE
Intervention: Orthopaedic surgeries (foot)
Description: stabilization of metatarsal and phalangeal osteotomies during treatment of hallux
Study NCT02447068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luma Light System
Description: The Luma Light System combines a NBUVB light with an occlusive dressing.
Study NCT02447068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Luma Light
Description: NBUVB light
Study NCT01661621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detrusitol 4 mg QD
Description: Group 1
Study NCT01661621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg QD
Description: Group 2
Study NCT01455259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCD40L
Description: Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
Study NCT00763568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
Study NCT00763568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
Study NCT01433991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golvatinib
Description: Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
Study NCT01433991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
Study NCT01433991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will receive lenvatinib 24 mg (1\*4 mg capsule + 2\*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
Study NCT02447068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive Dressing
Description: Off-the-shelf occlusive dressing
Study NCT02171039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Study NCT01293357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90105
Description: Ointment
Study NCT02171039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Study NCT02171039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT00727909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid Treatments
Description: Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)
Study NCT02171039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT04386473 — intervention group
Intervention type: DEVICE
Intervention: pacemaker
Description: electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP
Study NCT04432181 — intervention group
Intervention type: OTHER
Intervention: ophthalmic examination
Description: ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
Study NCT00592072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium chain fatty acid (Octanoic and Decanoic acid)
Description: Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
Study NCT00592072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Splenda (Placebo Control)
Description: Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
Study NCT03588104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWER2DM system
Description: This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care
Study NCT00759850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Stent (DES)
Description: Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
Study NCT00759850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent (DES)
Description: Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
Study NCT01223924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01223924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: M2ES IV 7.5mg-90mg
Study NCT02537197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Regular opioid antagonist dosing of disordered gamblers
Study NCT01485237 — intervention group
Intervention type: OTHER
Intervention: We will compare the resources used by both groups
Description: The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
Study NCT03870698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic group
Description: The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
Study NCT01664533 — intervention group
Intervention type: DRUG
Intervention: Erlotinib
Description: Erlotinib was supplied as tablets in the retail product Tarceva.
Study NCT04828252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser treatment
Description: The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
Study NCT04828252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser treatment
Description: The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
Study NCT04828252 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low level laser treatment
Description: The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
Study NCT02119481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Study NCT02119481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive writing condition
Study NCT04232384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Paracentesis
Description: The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).
Study NCT04232384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roll Over Paracentesis
Description: Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
Study NCT01377376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197 and Erlotinib
Description: Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
Study NCT01377376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Erlotinib
Description: Oral twice daily administration of placebo and oral once daily administration of erlotinib
Study NCT04471337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: BAY1817080 will be administered orally as tablet.
Study NCT03259438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
Study NCT03259438 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living (CHIP + Pre-Train)
Description: The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
Study NCT02564081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching lower limb
Study NCT02564081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching Cervical
Study NCT03572257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Patients randomized to the study treatment group will received quetiapine at 0.5 mg/kg, three times a day for 10 days. Doses can be increased up to a maximum of 6 mg/kg/day, in increments of 0.5 mg/kg, based on the subject's clinical delirium symptoms. PRN doses of 0.5 mg/kg can be given up to three times a day based on the clinical judgement of the subject's ICU care team.
Study NCT04374032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metenkefalin + tridecactide
Description: ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection
Study NCT03588104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care as given to diabetes patients by the patient's diabetes care team.
Study NCT02282488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein formula
Study NCT02282488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein formula
Study NCT03572257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo group will be given an equivalent volume of sterile liquid or sugar pill, based on the individual subjects dosing preference or ability. Dosing will be done on the same schedule as the quetiapine group
Study NCT02530827 — intervention group
Intervention type: DRUG
Intervention: use of lipid-lowering drugs.
Description: The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
Study NCT04374032 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: The standard of care
Description: The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
Study NCT02052583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic hypothermia at 32 ° C
Study NCT02052583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic hypothermia at 34 ° C
Study NCT00871702 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD34-TK75 transduced donor lymphocytes
Study NCT02886338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Description: The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
Study NCT03130504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17α hydroxy progesterone caproate
Description: where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
Study NCT00871702 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sub Study - 18 FHBG PET/CT Scans
Description: Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
Study NCT04736836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin
Description: locally absorbed antibiotic
Study NCT02456571 — intervention group
Intervention type: DEVICE
Intervention: CTC biomarker expression prevalence
Study NCT02861118 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT00409396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urinary PGEm level
Description: Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
Study NCT00409396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal calprotectin
Description: Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
Study NCT02108522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus Specific T cells
Study NCT03966092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: * Bilateral Quatratus lumborum block is performed with ultra sound guidance. The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). Laterally, these three are merging to from fascia transversalis. Under fascia transversalis, we can see quadratus lumborum muscle. Punction point in lateral, 1cm in the plan separating quadratus lumborum block and fascia transversalis~* 20 ml of ropivacaïne 3.75mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised.
Study NCT01160224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW766944
Description: Drug: GW766944 (Active Drug Treatment)
Study NCT01160224 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is placebo to match.
Study NCT01699776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: 7.5 my b.id. by mouth for 12-14 weeks
Study NCT01699776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: 1.25 mg once a day by mouth, for 12-14 weeks.
Study NCT02876484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Study NCT02876484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic Acid
Study NCT02876484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Study NCT00937508 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking counseling
Description: Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
Study NCT00937508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking counseling
Description: Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
Study NCT00937508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: varenicline (an approved medication for smoking cessation)
Study NCT02553083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40 mg
Description: Nexium 40 mg twice daily for 14 days